Under the terms of the licence agreement, F-star Beta receives an exclusive licence for the generation of Fcab™ andbispecific antibodies(mAb2™) against certain oncology and immuno-oncology targets. In return, F-star will receive a combination of milestone payments and tiered royalties. “F-star created an asset-centric vehicle structure in October of 2013 to accelerate the development of a pipeline of proprietary cancer therapeutics, while enabling greater commercial and financial flexibility for the company and future partners,” said John Haurum, CEO of F-star. “We are extremely pleased with the speed and productivity of our proprietary Modular Antibody Technology™ platform. The efficiency of our R&D engine facilitates the development of a large number of novel therapeutic products, well beyond what a single company can develop. F-star Beta, as well as future asset-centric vehicles, is being established to create a flexible corporate structure to further enhance the opportunity to attract leading biopharmaceutical companies. This approach was recently successful with our lead programme FS102 and the related agreement with Bristol-Myers Squibb to obtain an option to acquire our first asset-centricvehicle, F-star Alpha Ltd.”
F-star Announces the Formation of Second Asset-Centric Vehicle, F-star Beta Ltd
The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.
As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.